Drugs / Cavosonstat
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02934139 | Oct → Dec 2016 | cystic fibrosis | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02500667 | Jun → Aug 2015 | — | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02275936 | Feb → Jul 2015 | cystic fibrosis | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02227888 | Oct 2014 → Jan 2015 | cystic fibrosis | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02013388 | Feb → Dec 2014 | — | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04600778 | Feb → Dec 2021 | chronic obstructive pulmonary disease | GSNOR Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04129931 | Dec 2019 → Feb 2025 | asthma | University of North Carolina, Chapel Hill | Completed | Missed primary |
| Phase 2 | NCT02724527 | Apr 2016 → Apr 2017 | cystic fibrosis | Nivalis Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02589236 | Nov 2015 → Dec 2016 | cystic fibrosis | Nivalis Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cavosonstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04129931 ↗ |
| Known as | N91115 | “MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)” NCT02934139 ↗5“Cavosonstat (N91115) 200 mg twice daily (BID)” NCT02589236 ↗ |
| Action | Inhibit | “Alcohol dehydrogenase class III inhibitor” CHEMBL3989910 ↗1“inhibitor” PMID 28209466 ↗ Feb 2017 |
| Modality | Small molecule | — CHEMBL3989910 ↗ |
| Route | Oral | “single oral daily dose of 10 mg N91115 for 14 days” NCT02013388 ↗ |
| Target | ADH5 | “Alcohol dehydrogenase class III inhibitor” CHEMBL3989910 ↗ |
| Target | CFTR | “CFTR modulator that stabilizes CFTR” NCT02724527 ↗ |